| scholarly article | Q13442814 |
| P2093 | author name string | R Poupon | |
| J Giboudeau | |||
| A Loria | |||
| L Serfaty | |||
| J Guéchot | |||
| A Laudat | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| P304 | page(s) | 558-563 | |
| P577 | publication date | 1996-04-01 | |
| P1433 | published in | Clinical Chemistry | Q849687 |
| P1476 | title | Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis | |
| P478 | volume | 42 |
| Q30476922 | A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation |
| Q24816281 | Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus |
| Q36990696 | Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality |
| Q33665359 | Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients? |
| Q26825671 | Chronic hepatitis C and liver fibrosis. |
| Q38366999 | Circulating CO3-610, a degradation product of collagen III, closely reflects liver collagen and portal pressure in rats with fibrosis. |
| Q42196088 | Clinical Utility of Biomarkers of Liver Fibrosis |
| Q64235605 | Combining liver stiffness with hyaluronic acid provides superior prognostic performance in chronic hepatitis C |
| Q34650743 | Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C. |
| Q34098835 | Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring |
| Q38286648 | Diffusion Weighted MRI for Hepatic Fibrosis: Impact of b-Value |
| Q35777649 | Effect of Astragalus complanatus flavonoid on anti-liver fibrosis in rats |
| Q35544756 | Effects of silybum marianum on patients with chronic hepatitis C. |
| Q28068532 | Evaluation of liver fibrosis: "Something old, something new…" |
| Q33718945 | Fatty liver disease in children: eat now pay later. |
| Q37210696 | GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics |
| Q64251219 | Histological and biochemical evaluation of transforming growth factor-β activation and its clinical significance in patients with chronic liver disease |
| Q27021754 | Hyaluronic Acid: from biochemical characteristics to its clinical translation in assessment of liver fibrosis |
| Q26752723 | Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies |
| Q40707122 | Magnitude of contrast-enhanced ultrasonography as a noninvasive predictor for hepatic fibrosis: comparison with liver stiffness measurement and serum-based models. |
| Q35787865 | Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients |
| Q37511434 | Metabolic consequences of sleep-disordered breathing |
| Q38032835 | Molecular serum markers of liver fibrosis. |
| Q83291235 | New method for assessing liver fibrosis based on acoustic radiation force impulse: a special reference to the difference between right and left liver |
| Q33866383 | Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy |
| Q30421450 | Non invasive tools for the diagnosis of liver cirrhosis. |
| Q26744631 | Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? |
| Q42406716 | Non-invasive assessment of liver fibrosis |
| Q30474738 | Non-invasive assessment of liver fibrosis in chronic hepatitis C. |
| Q37192623 | Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms. |
| Q85623588 | Non-invasive diagnosis of liver fibrosis |
| Q26778033 | Non-invasive diagnosis of liver fibrosis and cirrhosis |
| Q36394872 | Non-invasive evaluation of hepatic fibrosis: don't count your chickens before they're hatched |
| Q35769146 | Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. |
| Q37420008 | Noninvasive assessment of liver fibrosis with combined serum aminotransferase/platelet ratio index and hyaluronic acid in patients with chronic hepatitis B. |
| Q36914350 | Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C. |
| Q36449160 | Noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis C. |
| Q34992341 | Paediatric cholestatic liver disease: Diagnosis, assessment of disease progression and mechanisms of fibrogenesis. |
| Q30990299 | Peroxiredoxin 2: a potential biomarker for early diagnosis of Hepatitis B Virus related liver fibrosis identified by proteomic analysis of the plasma |
| Q37204019 | Recent advances in the pathogenesis and diagnosis of liver fibrosis |
| Q36180551 | Relationship between clinical and pathologic findings in patients with chronic liver diseases |
| Q42855705 | Serum anti-modified citrullinated vimentin antibody concentration is associated with liver fibrosis in patients with chronic hepatitis |
| Q43036980 | Serum concentrations of insulin-like growth factor-I (igf-I) as a marker of liver fibrosis in patients with chronic hepatitis C. |
| Q92617180 | Serum miR-21 correlates with the histological stage of chronic hepatitis B-associated liver fibrosis |
| Q57705532 | Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases |
| Q33565557 | Usefulness of non-invasive markers for predicting significant fibrosis in patients with chronic liver disease |
| Q35208879 | Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study |
Search more.